Poseida Therapeutics

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in December 2014 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1 Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic TSCM-rich CAR-T for both autoimmune diseases and oncology Advancing innovative strategies to overcome the unique challenges of applying CAR-T to solid tumors Virtual R&D Day featuring partner Astellas Pharma and Poseida's leadership and scientific teams to be held today at 10:00am ET / 7:00am PT SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced plans to share progress across its clinical- and earlier-stage pipeline of differentiated T stem cell memory cells (TSCM)-rich allogeneic CAR-T therapies in oncology and autoimmune diseases during a virtual R&D Day to be held today at 10:00am ET / 7:00am PT. "We believe Poseida is well positioned to be a cell therapy leader based on the unique capabilities of our proprietary non-viral technology platform and our allogeneic TSCM-rich CAR-T approach," said Kristin Yarema, Ph.D.

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline

Does Poseida Therapeutics, Inc. (PSTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know

SAN DIEGO , Nov. 11, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced that the Company will participate in the following upcoming investor conferences: Stifel 2024 Healthcare Conference Date: Monday, November 18, 2024 Time: 10:20am ET Piper Sandler 36th Annual Healthcare Conference Date: Wednesday, December 4, 2024 Time: 12:00pm ET Webcasts will be available on the Investors & Media Section of Poseida's website, www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.

Poseida Therapeutics to Present at Two Upcoming Investor Conferences

Poseida Therapeutics, Inc. (PSTX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to loss of $0.35 per share a year ago.

Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates

Strong collaboration momentum with Roche expansion of CAR-T partnership and Astellas nomination of second solid tumor research program target  Cash flow positive for the first nine months of 2024; $130 million generated in milestone and upfront payments to-date  Presented positive interim Phase 1 results for RMAT-designated P-BCMA-ALLO1 with 91% overall response rate and differentiated safety profile in heavily pretreated relapsed/refractory BCMA-exposed and BCMA-naïve multiple myeloma patients Introduced P-BCMACD19-ALLO1 as wholly-owned program with compelling biologic rationale for autoimmune disease and hematological malignancies On track to deliver further updates across allogeneic CAR-T pipeline before year-end 2024, including presentations at the 66th American Society of Hematology Annual Meeting in December SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced updates and financial results for the third quarter ended September 30, 2024. "Poseida continues to make excellent progress across all of our key initiatives, highlighted by compelling data presentations from our pipeline of innovative, non-viral allogeneic cell therapy and genetic medicine programs, the expansion and advancement of our collaborations with Roche and Astellas, and our science-backed strategy to apply our platform to the large and growing opportunity for CAR-T in autoimmune diseases," said Kristin Yarema, Ph.D.

Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024

New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better target solid tumors will be presented at SITC Additional profiling of patient responses in P-BCMA-ALLO1 Phase 1 Arm C and preclinical P-CD19CD20-ALLO1 to be presented at ASH SAN DIEGO , Nov. 5, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced new preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM), along with platform enhancements aimed at enhancing potency and improving targeting of solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting in Houston, November 6-10. Additionally, the Company announced presentations at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition, which will be held December 7-10 in San Diego.

Poseida Therapeutics to Present Clinical and Preclinical Data on Investigational Allogeneic CAR-T Cell Therapies at SITC 2024 and ASH 2024

Data to be highlighted in a Distinguished Industry Oral Abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Scientific Meeting SAN DIEGO , Oct. 24, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune, and rare diseases, today announced the upcoming presentation of new preclinical data supporting the potential of P-KLKB1-101, a liver-directed genetic medicine that uses the Company's Cas-CLOVER™ Site-Specific Gene Editing System, for the treatment of patients with hereditary angioedema (HAE). The data showed high-fidelity KLKB1 gene editing for the targeted correction of HAE, the ability for controlled dose response, favorable tolerability and liver editing within the predicted therapeutic range.

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema

Allogeneic, TSCM-rich dual CAR-T for the treatment of hematologic malignancies, including multiple myeloma Nomination triggers $15 million milestone payment to Poseida, extending cash runway into early 2026 Poseida Cell Therapy R&D Day to take place on Thursday, November 14 at 7 am PT / 10 am ET SAN DIEGO , Oct. 17, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune, and rare diseases, today announced the nomination of a new development candidate under its collaboration with Roche. The nomination triggered a $15 million milestone payment from Roche to Poseida.

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche

Inclusion on list recognizes Poseida for employee sentiment and satisfaction SAN DIEGO , Oct. 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced its inclusion in Newsweek Magazine's annual America's Top Most Loved Workplaces® list, developed by Most Loved Workplace®, a division of Best Practice Institute (BPI). "At Poseida, our employees are essential to achieving our mission to boldly develop a new class of cell and gene therapies with the capacity to cure," said Kristin Yarema, Ph.D.

Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024

Positive interim results released from phase 1/1b study using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory Multiple Myeloma. The global multiple myeloma market is projected to reach $44.22 billion by 2032. Interim data update for use of P-CD19CD20-ALLO1 in ongoing phase 1 study targeting patients with B-cell malignancies expected in the 2nd half of 2024 pending coordination with Roche.

Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement

Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPRC5D-targeting treatment modality Differentiated P-BCMA-ALLO1 safety results with no dose-limiting toxicities, low rates of CRS and ICANS all Grade 2 or less and no graft vs. host disease or Parkinsonism P-BCMA-ALLO1 was recently granted Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and is being evaluated in a Phase 1/1b clinical trial in patients with relapsed/refractory multiple myeloma  who have previously received three or more prior lines of therapy Company to host webcast and conference call tomorrow at 1 p.m.

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

FDA evaluated RMAT application based on positive clinical data from ongoing Phase 1 study of P-BCMA-ALLO1; new clinical data from the study will be presented at the 21st International Myeloma Society Annual Meeting this month RMAT designation recognizes potential of P-BCMA-ALLO1 to address significant unmet needs of multiple myeloma patients and enables increased dialogue with FDA throughout the development process SAN DIEGO , Sept. 16, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to P-BCMA-ALLO1, an investigational stem cell memory T cell (TSCM)-based allogeneic CAR-T cell therapy in Phase 1/1b clinical development for the treatment of patients with relapsed/refractory multiple myeloma.

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma

Poseida Therapeutics shows promising early results in myeloma with their BCMA-directed allogeneic CAR T-cell therapy, achieving a 60% response rate in phase 1 trials. Financially stable with $30.5 million in cash, $207.3 million in short-term investments, and a $20 million milestone payment from Roche extending their cash runway. Strong partnerships with big pharma and deep cash reserves provide a solid foundation for continued development and potential non-dilutive funding.

Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024

Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem cell memory T cell (TSCM) platform Company to host conference call on Saturday, September 28, 2024, at 1 PM ET / 10 AM PT to review the P-BCMA-ALLO1 Phase 1 IMS oral presentation data Poseida initiates P-BCMA-ALLO1 Phase 1b clinical trial in patients with multiple myeloma, generating $20 million payment from Roche SAN DIEGO , Sept. 5, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, announced today that new clinical data from an ongoing Phase 1 study of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma will be presented in an oral session at the 21st International Myeloma Society (IMS) Annual Meeting, which is being held in Rio de Janeiro from September 25-28, 2024.

Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting

Reactivation of P-BCMA-101 CAR-T cells and a repeat stringent complete response (sCR) more than 3 years after original CAR-T therapy Demonstrates potential of stem cell memory T cells (TSCM), a key differentiator for Poseida's CAR-T programs  SAN DIEGO , Sept. 4, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, highlighted new data from a case study of a patient with relapsed multiple myeloma treated in a clinical trial of P-BCMA-101, the Company's original investigational T stem cell memory (TSCM)-rich BCMA targeting autologous CAR-T cell therapy.

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma

SAN DIEGO , Aug. 29, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the Company will participate in fireside chats at the following upcoming investor conferences in September: H.C. Wainwright 26th Annual Global Investment Conference Date: Monday, September 9, 2024 Time: 10:30am ET 2024 Cantor Global Healthcare Conference Date: Tuesday, September 17, 2024 Time: 1:20pm ET Live webcasts of the fireside chats will be available on the Investors & Media Section of Poseida's website, www.poseida.com.

Poseida Therapeutics to Present at Upcoming Investor Conferences

Poseida Therapeutics, Inc. (PSTX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.32 per share a year ago.

Poseida Therapeutics, Inc. (PSTX) Reports Q2 Loss, Tops Revenue Estimates

Continued Roche CAR-T partnership progress with agreement for Poseida to initiate Phase 1b portion of P-BCMA-ALLO1 clinical trial  Strong Astellas research collaboration momentum with nomination of first allogeneic solid tumor CAR-T program target On track to deliver meaningful clinical updates across allogeneic CAR-T pipeline in the second half of 2024 with first data readout anticipated at International Myeloma Society annual meeting in September Continued progress on non-viral genetic medicines pipeline, including FDA granting of INTERACT meeting for P-FVIII-101 SAN DIEGO , Aug. 5, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced updates and financial results for the second quarter ended June 30, 2024. "Poseida has delivered strong progress across our pipeline of innovative, non-viral allogeneic cell therapy and genetic medicine programs so far in 2024, setting the stage for significant potential catalysts in the second half of the year," said Kristin Yarema, Ph.D.

Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024

AbCellera Biologics

Lexicon Pharmaceuticals

MeiraGTx Holdings plc

Tenaya Therapeutic

Penny stocks represent an interesting investment opportunity.

5 Penny Stocks With 250% Upside in 1 Year According to Wall Street

Are You Looking for a Top Momentum Pick? Why Poseida Therapeutics, Inc. (PSTX) is a Great Choice

SAN DIEGO , July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that the Company's President and Chief Executive Officer, Kristin Yarema, Ph.D., will participate in a virtual fireside chat at the Stifel 2024 Virtual Cell Therapy Forum on Tuesday, July 9, 2024 at 7:55am PT | 10:55am ET.

Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum

SAN DIEGO , June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced that its virtual Annual Meeting of Stockholders (the "Annual Meeting") will be held on Monday, June 17, 2024 at 1:00 p.m. PT. The Annual Meeting will be held through a live webcast.

Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders

Expanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeting solid tumors Generated $95 million in milestone and upfront payments to-date in 2024, including $50 million from Astellas collaboration and $45 million from continued execution in the Company's CAR-T partnership with Roche   Presented promising early data at AACR demonstrating clinical responses with P-BCMA-ALLO1 in multiple myeloma patients following progression after prior BCMA-targeted therapy Presented non-human primate (NHP) data at ASGCT highlighting favorable safety and high-fidelity liver editing for lead non-viral investigational genetic medicine, P-KLKB1-101 SAN DIEGO , May 14, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2024.  "We see 2024 as a breakout year for Poseida as we make great strides across our cell therapy and genetic medicine programs and continue to cultivate and expand high value collaborations that highlight Poseida's role as the partner of choice in allogeneic CAR-T," said Kristin Yarema, Ph.D.

Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024

Early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic range with a favorable safety and tolerability profile Preclinical P-FVIII-101 data highlight sustained Hemophilia A correction following a single dose and support potential for repeat dosing and precise tuning of Factor VIII levels Promising early data further validate Company's fully non-viral delivery platform and transposon technologies SAN DIEGO , May 9, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today highlights new preclinical data supporting the potential of its fully non-viral lead genetic medicines programs and related platform technologies. The data was included in three oral and three poster presentations at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting, being held in Baltimore, MD and virtually on May 7-11, 2024.

Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting

Astellas Pharma Inc

- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid tumors - TOKYO and SAN DIEGO , May 1, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO: Kristin Yarema, "Poseida") today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies. Poseida is advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases.

News for Poseida Therapeutics Stock (PSTX)